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Edited by Stuart FergusonAbstract Oligopeptidase B (OpdB) from Trypanosoma brucei
is a candidate therapeutic target in African trypanosomiasis.
OpdB is an atypical serine peptidase, since activity is inhibited
by thiol-blocking reagents and enhanced by reducing agents.
We have identiﬁed C256 as the reactive cysteine residue that
mediates OpdB inhibition by N-ethylmaleimide and iodoacetic
acid. Modeling studies suggest that C256 adducts occlude the
P1 substrate-binding site, preventing substrate binding. We fur-
ther demonstrate that C559 and C597 are responsible for the
thiol-enhancement of OpdB activity. These studies may facilitate
the development of speciﬁc OpdB inhibitors with therapeutic po-
tential, by exploiting these unique properties of this enzyme.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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African trypanosomes contain a serine oligopeptidase, oligo-
peptidase B (OpdB) that cleaves oligopeptides on the C-termi-
nal side of basic residues [1], and is implicated in the
pathogenesis of African trypanosomiasis, since it is released
into the bloodstream of infected mammalian hosts [2]. Since
OpdB is not inhibited by endogenous serine peptidase inhibi-
tors in the host bloodstream [3], it retains catalytic activity
and thus participates in the pathogenesis of African trypanoso-
miasis through anomalous degradation of host peptide hor-
mones [4].
Oligopeptidase B from T. b. brucei has also been identi-
ﬁed as a target of several drugs used to treat African try-
panosomiasis. It is inhibited by the aromatic diamidines
pentamidine and diminazene, and the sulfonated naphthylu-Abbreviations: AMC, 7-amino-4-methylcoumarin; Cbz, carbobenzyl-
oxy; DTT, dithiothreitol; GSH, reduced glutathione; IAA, iodoacetic
acid; IAN, iodoacetamide; kass, apparent second-order inhibition rate
constant; NEM, N-ethylmaleimide; OpdB, oligopeptidase B; pCMB,
para-chloromercuribenzoate; POP, prolyl oligopeptidase; WT, wild-
type
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several peptidyl chloromethylketones and peptidyl a-amin-
oalkyl phosphonate diphenyl esters exhibited anti-trypanoso-
mal activity, both in vitro and in vivo [6]. These ﬁndings
suggested that the potential of OpdB as a therapeutic target
warranted further study. However, the P4–P1 speciﬁcity of
OpdB parallels that of many mammalian plasma serine pep-
tidases, including members of the blood clotting and com-
plement cascades [1,7]. This parallel speciﬁcity of OpdB
and several trypsin-like serine peptidases in the host plasma
has hampered our eﬀorts to develop speciﬁc OpdB inhibi-
tors with therapeutic potential. For example, the peptidyl
a-aminoalkyl phosphonate diphenyl esters referred to above
also prolong the prothrombin and activated partial throm-
boplastin time in mice [8], probably accounting for the ob-
served toxicity of these compounds when used to treat
experimental trypanosome infections in a rodent model [6].
These ﬁndings have led us to explore other unique phys-
ico-chemical properties of OpdB, which distinguish OpdB
from other mammalian plasma serine peptidases, in the
hope that these properties will facilitate the development
of speciﬁc inhibitors that selectively target OpdB without
aﬀecting the activity of other mammalian host serine pepti-
dases. One such property is the pronounced sensitivity of
OpdB to reagents that react with the thiol groups of cys-
teine residues.
Unlike most serine peptidases, the activity of OpdB isolated
from two important pathogenic African trypanosomes, T. b.
brucei [1] and T. congolense [9] is inhibited by thiol-blocking re-
agents, and is enhanced by reducing agents applied at low mil-
limolar concentrations. The mechanisms underlying these two
phenomena have not been elucidated. The T. brucei primary
sequence contains 14 cysteine residues [1] and it is likely that
thiol-blocking reagents and reducing agents act on one or
more of these 14 residues, thereby causing the observed inhibi-
tion and activation, respectively. In this study we set out to
identify which cysteine residues of OpdB were responsible for
mediating these eﬀects.2. Materials and methods
2.1. Isolation of OpdB from T. brucei
Oligopeptidase B was isolated from T. b. brucei ILTat1.1 lysates as
described previously [1]. Active enzyme concentration was determined
with 4-methylumbelliferyl-p-guanidinobenzoate [1].blished by Elsevier B.V. All rights reserved.
Table 1
Mutagenic primers used to introduce cysteine mutations into T. brucei
OpdB
Mutant Sequence
C117S 5 0-GTACAAGCTTCATTCTCGCGTACCGGCC-30
C147S 5 0-GGCAAATCTTTTTCTGTCGTGGGTTGC-30
C151S 5 0-TGTGTCGTGGGTTCCGTGGCGCCCGCC-30
C169S 5 0-TCCGTTGATTACAGCGGGGATGAGGTG-30
C202S 5 0-CCCAATGCCGAATCCTTCTTTTACATTAC-30
C231S 5 0-GTGAAGATGTATCCCTCTACACCGAC-3 0
C256A 5 0-GCTGATCATTGCCTCTATGTCATC-3 0
C256G 5 0-GCTGATCATTGGCTCTATGTCATC-30
C256S 5 0-GACGCTGATCATTTCCTCTATGTCATCAG-30
C310S 5 0-CAAATAAAGACAAGTCCGTGAATGGTAAG-30
C393S 5 0-GCCCATGTGGTTAGTTCTCAAATGAAG-30
C446S 5 0-GAAGAATTACGTTAGTCGGAGGGAGTTG-30
C488S 5 0-CCTACGGCATTTCCATTGAGCCTGAG-3 0
C542S 5 0-GGACTTTATTGCATCCGCGGAGCACC-3 0
C559S 5 0-GCGCAGCTTTCTTCCGAGGGAAGAAGTGC-30
C597S 5 0-CGTAATGACAACCATGTCTGATCCAAGCATTCC-30
The Cysﬁ Ser codon is underlined, and the base-pair changes are
illustrated in bold type. Only the forward (sense) primer is indicated.
Fig. 1. Inhibition of OpdB by thiol-blocking reagents. (A) Native
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A pET19b::opdB expression plasmid for production of recombi-
nant N-terminal polyhistidine-tagged T. brucei OpdB [1] was used
for the generation of site-directed OpdB variants, performed as
described previously [10], employing the mutagenic oligonucleotide
primers in Table 1. Point mutations were conﬁrmed by DNA
sequencing from the pET19B T7 terminator with a universal T7 ter-
minator primer (5 0-GCT AGT TAT TGC TCA GCG G-3 0), or using
forward sequencing primers 5 0-CTA CAC GCG TGA TGT AAA
GGG-3 0 or 5-CGG TGG GTG TGG GGA GGT CGG-3 0, corre-
sponding to base-pairs 219–240 and 632–652, respectively of the T.
brucei opdB open reading frame [1]. In selected cases (the C256A,
C256G and C256S constructs) the entire coding sequence was se-
quenced in both directions to check for undesired point mutations.
2.3. Hyper-expression of site-mutated OpdB variants
For expression, opdBmutant constructs were transformed into Esch-
erichia coli BL21 kDE3 and recombinant protein expressed as de-
scribed previously [10]. Protein purity was evaluated by Tris–Tricine
SDS–PAGE. The OpdB variants (2 lg) were resolved on a 10%
Tris–Tricine SDS–PAGE gel with or without prior reduction (boiling
in 100 mM dithiothreitol (DTT)).
2.4. Determination of amidolytic activity
Activity of OpdB was determined against 5 lM N-carbobenzyloxy
(Cbz)-L-Arg-L-Arg-7-amido-4-methylcoumarin (AMC) at 37 C in
50 mM Tris–Cl/5 mM DTT, pH 8.0 in an Hitachi F-2000 spectroﬂuo-
rimeter (kex = 370 nm, kem = 460 nm) [1]. Kinetic analyses (kass, Km
and kcat) were undertaken as described in [1]. Intergroup diﬀerences
were estimated by a statistical analysis of variance (ANOVA). Fishers
protected least-signiﬁcant diﬀerence test was employed to compare
individual groups. Diﬀerences within the same group were evaluated
with Students t test.
2.5. Protein sequence alignments and molecular modeling
Protein sequences were aligned with the CLUSTAL W software
from the MEGALIGN program (DNASTAR, Madison, WI), with a
PAM250 weight table set with the following parameters: ktuple = 1,
gap penalty = 3, and gap window = 5 [11]. Molecular modeling proce-
dures are described in detail in [12], and are indicated in the legend to
Fig. 3A.OpdB puriﬁed from T. brucei lysates (open bars) and recombinant
His6-tagged WT OpdB (closed bars) were pre-incubated with pCMB,
NEM, IAA and IAN (10 mM), prior to assessment of hydrolytic
activity. Data reﬂect mean residual activity ± S.D (n = 3). (B) The
time-course for the inactivation of WT His6-tagged OpdB (solid line)
and its C256S variant (dashed line) by 5 mM NEM (j) or 5 mM IAA
(r). Data reﬂect mean residual activity ± S.D. (n = 3). WT, wild-type.3. Results
All recombinant OpdB variants migrated as a single band
of 80 kDa on SDS–PAGE under reducing and under non-reducing conditions (data not shown). The Km and kcat val-
ues for native and recombinant wild-type (WT) OpdB were
in excellent agreement, and both enzymes were inactivated
by para-chloromercuribenzoic acid (pCMB), N-ethylmalei-
mide (NEM), iodoacetic acid (IAA) and iodoacetamide
(IAN) to comparable extents (Fig. 1A). Thus, the poly-histi-
dine aﬃnity tag did not alter the enzymatic properties of
OpdB.
All cysteine residues in the OpdB sequence were separately
converted to serine residues. All site-mutated Cysﬁ Ser vari-
ants were catalytically active against Cbz-Arg-Arg-AMC,
exhibiting an average kcat/Km of 62 ± 14 s
1 lM (data not
shown), when assayed in 50 mM Tris–Cl, pH 8, at 37 C. Thus,
the cysteine replacements did not appreciably impair the cata-
lytic competence of the OpdB variants. The apparent second-
order inhibition rate constant (kass) values for the association
of all OpdB variants with IAA and NEM were comparable
to the WT enzyme (kass values in the range of 1.5–
2.5 M1 s1), except for the C256S variant, which exhibited a
750-fold reduction in kass for IAA (0.0021 ± 0.0008 M
1 s1)
and more than 1000-fold reduction in kass for NEM
(0.0012 ± 0.0010 M1 s1). Overall, pCMB exhibited a faster
rate of association with OpdB variants than did IAA or
NEM (average kass 20–30 M
1 s1), and again the C256S
was more resistant to pCMB inhibition (16 ± 2 M1 s1), how-
ever, this eﬀect was less signiﬁcant (P < 0.05) than were the
Fig. 2. Enhancement of OpdB activity by reducing agents. (A) Native
OpdB puriﬁed from T. brucei lysates (open bars) and recombinant
polyhistidine-tagged WT OpdB (closed bars) were pre-incubated with
DTT, GSH or L-cysteine (Cys), after which residual activity against
Cbz-Arg-Arg-AMC was determined. (B) Dose-dependence for the
enhancement of OpdB activity by DTT (j), GSH (r) and Cys (m). In
both panels, data reﬂect the mean activity ± S.D. (n = 3). (C)
Recombinant polyhistidine-tagged OpdB variants (150–200 fmol
active enzyme), were pre-incubated in the absence (open bars), or
presence of 5 mM DTT (closed bars) or GSH (hatched bars) prior to
assessment of hydrolytic activity. Data reﬂect the mean kcat/Km ± S.D.
(n = 5). WT, wild-type. \\, P < 0.001; \, P < 0.05, with respect to OpdB
that was not treated with any reducing agent (open bars).
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The C256S OpdB variant was remarkably resistant to inactiva-
tion by both NEM and IAA, demonstrating a negligible (1–
2%) reduction in activity after a ﬁve min pre-incubation with
either NEM or IAA at 5 mM (Fig. 1B). These data suggested
that C256 was the reactive cysteine residue responsible for the
inactivation of OpdB by NEM and IAA.
Serine (CH2OH side-chain) is structurally very similar to
cysteine (CH2SH side-chain). Furthermore, serine and cys-
teine are both uncharged, polar residues, and are thus likely
to have similar physico-chemical properties. Hence, we con-
sidered serine a good cysteine mimic, and routinely em-
ployed serine in our cysteine conversions. However, in the
event that a serine substitution caused a relevant conforma-
tional change in OpdB, we also replaced C256 with an ala-
nine residue (C256A) and a glycine residue (C256G). Both
of these variants behaved in a manner comparable with
the C256S variant, and exhibited kass values with IAA of
0.0037 ± 0.0011 and 0.0045 ± 0.0024 M1 s1 for the C256A
and C256G variants, respectively. Similarly, in the presence
of NEM, the C256A and C256G variants exhibited kass val-
ues of 0.0007 ± 0.0002 and 0.0005 ± 0.0004 M1 s1, respec-
tively. These data support our contention that C256 is the
key residue involved in mediating OpdB inhibition by IAA
and NEM.
The activity of native and recombinant WT OpdB was en-
hanced by 5 mM DTT, glutathione (GSH) and L-cysteine
(Fig. 2A), indicating that the poly-histidine aﬃnity tag did
not alter thiol-activation properties. Half-maximal enhance-
ment of recombinant WT OpdB occurred at sub-millimolar
DTT and GSH concentrations (0.63 mM; Fig. 2B). Under
non-reducing and reducing (10 mM DTT) conditions, OpdB
eluted from a Sephacryl S-200 HR molecular exclusion column
at a molecular mass corresponding to 80 kDa, the size of
monomeric OpdB (data not shown). Thus, OpdB does not
form inactive multimers under non-reducing conditions.
The kcat/Km values for all OpdB variants treated with
DTT and GSH were comparable to the WT enzyme, except
for the C559S and C597S variants, which exhibited a signif-
icant (P < 0.01) reduction in the degree of activation. WT
OpdB exhibited a kcat/Km value of 468 ± 19 s
1 lM in the
presence of 5 mM DTT, while the kcat/Km values for the
C256S, C559S and C597S variants were reduced to
418 ± 22, 190 ± 12 and 254 ± 8 s1 lM, respectively. Simi-
larly, in the presence of 5 mM GSH, WT OpdB exhibited
a kcat/Km value of 388 ± 18 s
1 lM, while C256S, C559S
and C597S variants were reduced to 312 ± 6, 194 ± 16 and
211 ± 10 s1 lM, respectively. A C559:597S double-variant
exhibited a meagre two-fold elevation in kcat/Km in the pres-
ence of DTT, and 1.8-fold in the presence of GSH (Fig.
2C). Even less eﬀect was seen in the C256:559:597S triple-
variant, which exhibited a 0.8- and 0.7-fold elevation in
kcat/Km in the presence of DTT and GSH, respectively
(Fig. 2C). However, even this triple C256:559:597S OpdB
variant still exhibited a signiﬁcant (P < 0.05) increase in
activity in the presence of 5 mM DTT and 5 mM GSH
when compared with OpdB that was not treated with any
reducing agent (Fig. 2C). These data conﬁrm that C559,
C597 and perhaps C256 are primarily responsible for the
thiol-activated activity of OpdB, however, it appears that
one or more additional cysteine residues contribute, albeit
weakly, to this phenomenon.4. Discussion
Oligopeptidase B from T. brucei was potently inactivated by
IAA and NEM, while IAN had less eﬀect. We have previously
speculated [1] that thiol-blocking agents may inhibit OpdB by
alkylation of C559, which lies four residues N-terminal to the
active-site serine residue (Fig. 1), and proposed that alkylation
of C559 would impair catalysis given its proximity to the
active-site serine. In the present study, we demonstrate that
2194 R.E. Morty et al. / FEBS Letters 579 (2005) 2191–2196inhibition by IAA and NEM was mediated exclusively by
C256. Our original suggestion of C559 was therefore incorrect.
The agents IAA and NEM do not inhibit OpdB from T. cruzi
[13], E. coli [14] and Moraxella lacunata [15]. Interestingly,
OpdBhomologues from these three organismsdonot have a cys-
teine residue at position C256, where it is replaced by a glycine,
tyrosine and histidine residue, respectively (Fig. 3B). Similarly, a
reactive cysteine residue in porcine prolyl oligopeptidase (POP)
is not conserved in two prokaryotic POPs, represented in Fig. 3B
by POP from Aeromonas hydrophila and Flavobacterium men-
ingosepticum. This supports our contention that C256 is respon-
sible for the inhibitory properties of IAA and NEM.
An excellent computer model of E. coli OpdB has been gen-
erated [16], based on the structure of porcine POP [17].
Employing a similar model of the T. brucei enzyme (Fig.
3A), we observed that C256 was brought into close proximity
to residues E607 and E609. These two residues are key residues
that bind to the P1 substrate residue [10]. Thus, any chemical
adduct that reacts and binds to C256 could interfere with the
binding of the P1-substrate residue to the E607/E609 pair.
Alklyation of C256 by N-ethylmaleimide would introduce a
large, bulky adduct [18], which could block substrate binding
by steric hindrance. The situation is probably diﬀerent for
IAN (ICH2COONH2) and for IAA (ICH2COO
), since both
molecules are very small, and have a similar size, but are veryFig. 3. Cysteine 256 in T. brucei OpdB. (A) Homology modeling of T. bruce
was prepared with MolScript exactly as described previously [12], using the
carboxyl dyads of T. brucei OpdB: E607 and E609 (for P1) and E490 and E492
residues (POP residues are indicated in brackets), bound in a complex with
Phe(NO2)-Ala-NH2) that is shown darker than the oligopeptidase residues. T
(S563), are also indicated. (B) Alignment of the region surrounding C256 for r
peptidases. The full-length T. brucei OpdB [1] was aligned with the full-lengt
the full-length POP sequences from A. hydrophila [26], F. meningosepticum [2
The reactive T. brucei C256 is indicated by an (a), while a comparable reactdiﬀerent with respect to OpdB inhibition properties. IAA was
strongly inhibitory, while IAN was not. Alkylation of C256 by
IAA would introduce a negatively charged CH2COO
 adduct
[19]. This would place an additional negatively charged cluster
close to the E607/E609 pair, and may interfere with the correct
binding or ‘‘docking’’ of the substrate at the active-site, per-
haps placing the scissile bond in an unfavorable position for
catalysis. In contrast, IAN would introduce a small neutral
(i.e., uncharged) amide group at the same site, which does
not appear to impede OpdB activity. In contrast to NEM,
IAA and IAN, the pCMB was a much faster inhibitor of
OpdB, and its activity was not restricted to C256. These data
are consistent with the much more reactive nature of pCMB,
in comparison with NEM, IAA and IAN [20]. Furthermore,
pCMB alkylates both cysteines and free amines, perhaps
explaining its more dramatic eﬀect [20].
Since all of our cysteine to serine OpdB variants displayed
catalytic properties similar to those exhibited by the WT en-
zyme (as reﬂected by the kcat and Km values for the hydrolysis
of Cbz-Arg-Arg-AMC by each variant in the absence of reduc-
ing agents), it was unlikely that the cysteine to serine conver-
sions caused structural changes in the enzyme that impaired
catalytical capacity. However, since the replacement of some
cysteine residues with serine residues in prolyl endopeptidase
[21] and in thimet oligopeptidase [22] led to interference withi OpdB, based on the closely related POP structure. This stereo model
coordinates of Protein Data Bank entry 1e8n. The substrate-binding
(for P2) are shown (in black) superimposed on the corresponding POP
an octapeptide substrate (o-aminobenzoyl-Gly-Phe-Gly-Pro-Phe-Gly-
he OpdB reactive cysteine residue C256 and the catalytic serine residue
epresentative four members of the OpdB and POP subfamilies of serine
h OpdB sequences from T. cruzi [13], M. lacunata [15], E. coli [14], and
7] and Sus scrofa [28] using the CLUSTAL X alignment software [11].
ive cysteine residue in POP [21] is indicated by a (b).
R.E. Morty et al. / FEBS Letters 579 (2005) 2191–2196 2195catalytic competence, we addressed whether this may be the
case in our OpdB variants. Thus, we also constructed a
C256A and a C256G variant, in addition to the C256S variant.
However, in the case of OpdB, substitution of the reactive cys-
teine with alanine or glycine yielded similar kinetic data to
those obtained with the C256S variant. We therefore con-
cluded with conﬁdence that C256 is the reactive cysteine resi-
due responsible for the inactivation of OpdB by NEM and
IAA. We have now initiated studies that will explore the pos-
sibility of using peptide-based OpdB substrates modiﬁed with
thiol-reactive groups, to direct the alkylation of C256, thereby
combining OpdB substrate speciﬁcity and thiol-alkylation
properties to develop speciﬁc OpdB inhibitors.
A second property of OpdB that sets it aside from other ser-
ine peptidases is the ability of reducing agents to enhance cat-
alytic activity. This is typically a property of cysteine
peptidases, although some metallopeptidases, for example, thi-
met oligopeptidase [23], also exhibit activation by reducing
agents. Thimet oligopeptidase forms covalently associated
multimers through intermolecular disulﬁde bridges, with con-
comitant loss of catalytic power. Catalytic competence is re-
gained upon reduction of multimers back to monomers with
DTT [23]. Oligopeptidase B did not form dimers, or any other
kind of multimers, in the absence or presence of reducing
agents, which evident from its electrophoretic migration and
chromatographic behavior under non-reducing and reducing
conditions. Thus, the multimer« monomer model does not
apply to OpdB. It is not immediately apparent how the cys-
teine residues of OpdB mediate the enhancing eﬀects of DTT
and GSH. Reduction or rearrangement of intramolecular
(i.e., within the same OpdB molecule) disulﬁde bridges may
promote conformational changes with activity-enhancing ef-
fects, alternatively, the thiol groups of free cysteines may form
mixed disulﬁdes with small molecules, which are reduced to
free thiols in the presence of DTT or GSH. The determination
of the three-dimensional structure of OpdB, which is currently
underway in our laboratories, may help to explain this activity-
enhancing eﬀect of reducing agents.
Could the thiol-sensitivity of OpdB be physiologically rele-
vant? African trypanosomes contain millimolar concentrations
of reducing agents in the cytosol. In T. brucei, assuming a cell
volume of 5.8 ll per 108 cells [24], total cytosolic GSH concen-
trations exceed 1 mM, and this GSH exists either freely, or as a
unique spermidine conjugate, trypanothione [N1,N8-bis(gluta-
thionyl)spermidine] [25]. Thus, the trypanosome cytosol is a
potently reducing environment, containing suﬃcient GSH to
make the thiol-enhancing properties of OpdB physiologically
relevant, a phenomenon that may exist to regulate OpdB activ-
ity in the parasites.
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